Molecular Diagnostics News and Research

RSS

PDI Expands Focus With Mdx Commercialization Deal

...

22 Aug 2013

German researchers discover miRNAs, which determine malignancy of urinary bladder cancers

German researchers have identified four biomarkers that correctly determine malignancy of urinary bladder cancers and contribute to the accurate prediction of patient outcomes. Their results are published in the September issue of The Journal of Molecular Diagnostics.

16 Aug 2013

Understanding the movement of neurons sheds light on how cancer cells invade health tissues

The invasion of brain-tumor cells into surrounding tissue requires the same protein molecule that neurons need to migrate into position as they differentiate and mature, according to new research from the University of Illinois at Chicago College of Medicine and published August 7 in the online journal PLOS ONE.

8 Aug 2013

NanoString announces Early Access Program for nCounter Elements used in translational research

NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an Early Access Program for nCounter Elements™, a line of General Purpose Reagents (GPRs) developed specifically to meet the needs of translational research and clinical laboratories.

From NanoString Technologies 2 Aug 2013

Sequenom CMM, CombiMatrix sign collaboration agreement to market CMA testing for NIPT

Sequenom, Inc., a life sciences company providing innovative diagnostic testing and genetic analysis solutions, and CombiMatrix Corporation, a molecular diagnostics laboratory performing DNA-based testing services for developmental disorders and cancer, today jointly announced that the Sequenom Center for Molecular Medicine LLC and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis testing services to broaden and confirm the results of noninvasive, prenatal testing to physicians and their patients.

1 Aug 2013

Rheonix, Life Technologies sign joint development agreement for molecular testing platform

Rheonix, Inc., a developer of fully automated molecular testing solutions, and Life Technologies Corp., a global leader in the life sciences tools and diagnostic markets, have entered into a joint development agreement to introduce a molecular testing platform for their Applied Markets business.

1 Aug 2013

EKF Diagnostics introduces STAT-Site M ß-HB strip test for DKA assessment

EKF Diagnostics, the global in vitro diagnostics business, announces the worldwide launch of the new STAT-Site M ß-HB, following successful CE marking.

From EKF Diagnostics 25 Jul 2013

Scientists develop histology expression predictor for most common types of lung cancer

Knowing what type of lung cancer a patient has is critical to determine which drug will work best and which therapies are safest in the era of personalized medicine. Key to making that judgment is an adequate tumor specimen for the pathologist to determine the tumor's histology, a molecular description of a tumor based on the appearance of cells under a microscope.

17 Jul 2013

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.

From QIAGEN Manchester Limited 15 Jul 2013

PathoQuest closes new fundraising of EUR 3.8 million

PathoQuest, a new generation molecular diagnostics company that offers a new approach based on NGS (Next Generation Sequencing) in the field of infectious diseases, announces today the closing of a new fundraising of EUR 3.8 million.

12 Jul 2013

Director of Molecular Diagnostics receives AMP 2013 Leadership Award

Jan A. Nowak, PhD, MD, has been awarded the Association for Molecular Pathology 2013 Leadership Award. This is the highest honor that AMP gives exclusively to one of its members - one who has demonstrated exceptional leadership in the accomplishment of the mission and vision of AMP.

1 Jul 2013

New non-invasive test measures methylation of SDC2 gene, detects 87% of colorectal cancer

The average 5-year survival for colorectal cancer (CRC) is less than 10% if metastasis occurs, but can reach 90% if detected early. A new non-invasive test has been developed that measures methylation of the SDC2 gene in tissues and blood sera.

10 Jun 2013

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

Diaxonhit, XDx agree to market and perform AlloMap Molecular Expression Testing in Europe

Diaxonhit, the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, announced today that they have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap) in Europe.

4 Jun 2013

Experts to kick off Big Ten Cancer Research Consortium in Chicago

In athletics, the Big Ten universities compete against each other, but now many will join together against a common foe: cancer.

1 Jun 2013

Good Start Genetics gets $28M loan from Capital Royalty

Good Start Genetics, Inc., an innovative molecular diagnostics company that has developed the new gold standard in carrier screening, today announced that it has closed a non-dilutive loan facility for up to $28 million of capital from Capital Royalty L.P.

8 May 2013

New assays are effective in managing patients with influenza virus infection

Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly.

18 Apr 2013

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.

9 Apr 2013

Molecular diagnostic testing in lung cancer offers new hope for patients

The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad.

4 Apr 2013

First multi-gene DNA sequencing test launched for cancer patients

The first multi-gene DNA sequencing test that can help predict cancer patients' responses to treatment has been launched in the National Health Service, thanks to a partnership between scientists at the University of Oxford and Oxford University Hospitals NHS Trust.

26 Mar 2013